Literature DB >> 17903697

Effects of aldosterone and angiotensin II receptor blockade on cardiac angiotensinogen and angiotensin-converting enzyme 2 expression in Dahl salt-sensitive hypertensive rats.

Yoshiyu Takeda1, Aoshuang Zhu, Takashi Yoneda, Mikiya Usukura, Hiroyuki Takata, Masakazu Yamagishi.   

Abstract

BACKGROUND: We previously reported that a high-sodium diet activates the local renin-angiotensin-aldosterone system (RAAS) in cardiovascular tissues of Dahl salt-sensitive hypertensive (DS) rats. Angiotensin-converting enzyme 2 (ACE2) is a novel regulator of blood pressure (BP) and cardiac function. The effect of blockade of aldosterone or angiotensin II (Ang II) on cardiac angiotensinogen and ACE2 in DS rats is unknown.
METHODS: The BP, plasma renin activity (PRA), plasma aldosterone concentration (PAC), heart weight, endothelium-dependent relaxation (EDR), and messenger RNA (mRNA) levels of collagen III, angiotensinogen, ACE, and ACE2 in the heart were measured in DS rats and in Dahl salt-resistant (DR) rats fed high or low salt diets. The rats were treated orally with or without eplerenone (100 mg/kg/d), candesartan (10 mg/kg/d), or both drugs combined for 8 weeks.
RESULTS: A high salt diet increased BP (140%), heart/body weight (132%), and collagen III mRNA levels (146%) and decreased PRA and PAC concomitant with increased expression of cardiac angiotensinogen mRNA and decreased mRNA levels of ACE2 in DS rats. Eplerenone or candesartan significantly decreased the systolic BP from 240 +/- 5 mm Hg to 164 +/- 4 mm Hg or to 172 +/- 10 mm Hg, respectively (P < .05). Eplerenone or candesartan partially improved heart/body weight and cardiac fibrosis, improved EDR and decreased cardiac ACE and angiotensinogen mRNA levels in DS rats. Candesartan increased ACE2 mRNA levels in the heart. Combination therapy normalized BP and further improved cardiac hypertrophy, fibrosis, and EDR.
CONCLUSIONS: In DS rats, blockade of aldosterone or Ang II protects cardiac hypertrophy and fibrosis by inactivation of the local RAAS in the heart.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17903697     DOI: 10.1016/j.amjhyper.2007.05.008

Source DB:  PubMed          Journal:  Am J Hypertens        ISSN: 0895-7061            Impact factor:   2.689


  25 in total

Review 1.  Targeting cardiac fibroblasts to treat fibrosis of the heart: focus on HDACs.

Authors:  Katherine B Schuetze; Timothy A McKinsey; Carlin S Long
Journal:  J Mol Cell Cardiol       Date:  2014-03-11       Impact factor: 5.000

Review 2.  Proteolytic activation of the epithelial sodium channel and therapeutic application of a serine protease inhibitor for the treatment of salt-sensitive hypertension.

Authors:  Kenichiro Kitamura; Kimio Tomita
Journal:  Clin Exp Nephrol       Date:  2011-11-01       Impact factor: 2.801

Review 3.  Aldosterone: role in the cardiometabolic syndrome and resistant hypertension.

Authors:  Adam Whaley-Connell; Megan S Johnson; James R Sowers
Journal:  Prog Cardiovasc Dis       Date:  2010 Mar-Apr       Impact factor: 8.194

4.  Decreased cardiac Ang-(1-7) is associated with salt-induced cardiac remodeling and dysfunction.

Authors:  Jasmina Varagic; Sarfaraz Ahmad; K Bridget Brosnihan; Leanne Groban; Mark C Chappell; E Ann Tallant; Patricia E Gallagher; Carlos M Ferrario
Journal:  Ther Adv Cardiovasc Dis       Date:  2009-11-27

5.  Eplerenone inhibits the intracrine and extracellular actions of angiotensin II on the inward calcium current in the failing heart. On the presence of an intracrine renin angiotensin aldosterone system.

Authors:  Walmor C De Mello; Yamil Gerena
Journal:  Regul Pept       Date:  2008-06-08

Review 6.  Myofibroblast-mediated mechanisms of pathological remodelling of the heart.

Authors:  Karl T Weber; Yao Sun; Syamal K Bhattacharya; Robert A Ahokas; Ivan C Gerling
Journal:  Nat Rev Cardiol       Date:  2012-12-04       Impact factor: 32.419

Review 7.  Are we poised to target ACE2 for the next generation of antihypertensives?

Authors:  Anderson J Ferreira; Mohan K Raizada
Journal:  J Mol Med (Berl)       Date:  2008-05-01       Impact factor: 4.599

8.  Testosterone-dependent hypertension and upregulation of intrarenal angiotensinogen in Dahl salt-sensitive rats.

Authors:  Licy L Yanes; Julio C Sartori-Valinotti; Radu Iliescu; Damian G Romero; Lorraine C Racusen; Huimin Zhang; Jane F Reckelhoff
Journal:  Am J Physiol Renal Physiol       Date:  2009-02-11

9.  Impact of mineralocorticoid receptor blockade with direct renin inhibition in angiotensin II-dependent hypertensive mice.

Authors:  Atsushi Hashimoto; Yoshimichi Takeda; Shigehiro Karashima; Mitsuhiro Kometani; Daisuke Aono; Masashi Demura; Takuya Higashitani; Seigo Konishi; Takashi Yoneda; Yoshiyu Takeda
Journal:  Hypertens Res       Date:  2020-05-12       Impact factor: 3.872

Review 10.  Myofibroblast secretome and its auto-/paracrine signaling.

Authors:  Ritin Bomb; Mark R Heckle; Yao Sun; Salvatore Mancarella; Ramareddy V Guntaka; Ivan C Gerling; Karl T Weber
Journal:  Expert Rev Cardiovasc Ther       Date:  2016-02-17
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.